Literature DB >> 20687062

Vaccines for preventing cholera: killed whole cell or other subunit vaccines (injected).

Patricia M Graves1, Jonathan J Deeks, Vittorio Demicheli, Tom Jefferson.   

Abstract

BACKGROUND: Injected cholera vaccines are rarely used today, although they may have some benefit. It is valuable to summarize the evidence for effectiveness of injected cholera vaccines for comparison with newer oral vaccines (subject of a separate Cochrane Review).
OBJECTIVES: To evaluate killed whole cell (KWC) cholera vaccines and other inactive subunit vaccines (administered by injection) for preventing cholera and death, and to evaluate the adverse effects. SEARCH STRATEGY: In September 2008, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2008, Issue 3), EMBASE, and LILACS. We also searched reference lists and handsearched the journal Vaccine up to 1997. SELECTION CRITERIA: Randomized and quasi-randomized controlled trials comparing injected cholera vaccines (KWC or other inactive subunit) with placebo, control vaccines, or no intervention in adults and children irrespective of immune status or special risk category. DATA COLLECTION AND ANALYSIS: Two authors extracted data and assessed trial methodological quality independently. Dichotomous data were reported using the risk ratio (RR) with 95% confidence intervals (CI). Vaccine efficacies were also calculated (% vaccine efficacy = (1-RR) x 100%). MAIN
RESULTS: Sixteen trials, involving over one million adults, children and infants, fulfilled the inclusion criteria. Twenty-four comparisons reported on vaccine efficacy (cholera cases and/or deaths) and 11 comparisons considered adverse effects (nine reported on both). Compared to placebo, vaccinees had a reduced risk of death from cholera (RR 0.49, 95% CI 0.25 to 0.93; 837,442 participants) and a reduced risk of contracting cholera at 12 months (RR 0.52, 95% CI 0.42 to 0.65, random-effects model; 1,512,573 participants). This translates to an efficacy of 48%, 95% confidence interval 35% to 58%. Significant protection lasted for two years, even after only a single dose, and for three years with an annual booster. Children over five years and adults were protected for up to three years, while children under five years were protected for up to a year. Injected cholera vaccines were associated with more systemic and local adverse effects compared to placebo, but these were not severe or life-threatening. AUTHORS'
CONCLUSIONS: Injected cholera vaccines appear to be safe and relatively more effective than usually realized. Protection against cholera persists for up to two years following a single dose of vaccine, and for three years with an annual booster. However, they have been superseded by oral vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687062      PMCID: PMC6532721          DOI: 10.1002/14651858.CD000974.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  39 in total

1.  [A comparison of the serological effects of classical cholera vaccine and of purified fraction vaccine, with or without simultaneous yellow fever vaccine (author's transl)].

Authors:  C Gateff; A Dodin; J Wiart
Journal:  Ann Microbiol (Paris)       Date:  1975 Feb-Mar

2.  Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part I. Theory and practice of epidemiological models.

Authors:  B Cvjetanović; B Grab; K Uemura
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

3.  Dynamics of acute bacterial diseases. Epidemiological models and their application in public health. Part II. Epidemiological models of acute bacterial diseases.

Authors:  B Cvjetanović; B Grab; K Uemura
Journal:  Bull World Health Organ       Date:  1978       Impact factor: 9.408

4.  Preparation and evaluation of vibrio cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates.

Authors:  Osmir Cabrera; Miguel E Martínez; Maribel Cuello; Carmen R Soto; Tania Valmaseda; Bárbara Cedré; Gustavo Sierra González
Journal:  Vaccine       Date:  2006-04-12       Impact factor: 3.641

5.  Evaluating new vaccines for developing countries. Efficacy or effectiveness?

Authors:  J Clemens; R Brenner; M Rao; N Tafari; C Lowe
Journal:  JAMA       Date:  1996-02-07       Impact factor: 56.272

6.  Comparative study of reactions and serological response to cholera vaccines in a controlled field trial conducted in the USSR.

Authors:  P N Burgasov; A A Sumarokov; V L Lelikov; L M Marcuk; V G Fedenev; M N Dzaparidze; L T Karaeva; I I Derteva
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

Review 7.  Cholera vaccine: developmental strategies and problems.

Authors:  R K Bhadra; U Dasgupta; J Das
Journal:  Indian J Biochem Biophys       Date:  1994-12       Impact factor: 1.918

8.  Cholera incidence in a population offered cholera vaccination: comparison of cooperative and uncooperative groups.

Authors:  J C Azurin; M Alvero
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

9.  Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field.

Authors:  A S Benenson; W H Mosley; M Fahimuddin; R O Oseasohn
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

10.  Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta.

Authors:  A Das Gupta; R Sinha; D L Shrivastava; S P De; B L Taneja; M S Rao; A H Abou-Gareeb
Journal:  Bull World Health Organ       Date:  1967       Impact factor: 9.408

View more
  10 in total

1.  The time of cholera.

Authors:  David N Fisman; Kevin Laupland
Journal:  Can J Infect Dis Med Microbiol       Date:  2011       Impact factor: 2.471

2.  Cholera in travelers: shifting tides in epidemiology, management, and prevention.

Authors:  Katie Fillion; Maria D Mileno
Journal:  Curr Infect Dis Rep       Date:  2015-01       Impact factor: 3.725

3.  The Effect of Mass Azithromycin Distribution on Childhood Mortality: Beliefs and Estimates of Efficacy.

Authors:  Craig W See; Kieran S O'Brien; Jeremy D Keenan; Nicole E Stoller; Bruce D Gaynor; Travis C Porco; Thomas M Lietman
Journal:  Am J Trop Med Hyg       Date:  2015-09-21       Impact factor: 2.345

4.  The utility of human challenge studies in vaccine development: lessons learned from cholera.

Authors:  Debbie-Ann T Shirley; Monica A McArthur
Journal:  Vaccine (Auckl)       Date:  2011-10

5.  Cholera Outbreaks in Urban Bangladesh In 2011.

Authors:  Farhana Haque; M Jahangir Hossain; Subodh Kumar Kundu; Abu Mohd Naser; Mahmudur Rahman; Stephen P Luby
Journal:  Epidemiology (Sunnyvale)       Date:  2013-07-02

6.  A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice.

Authors:  Md Abu Sayeed; Meagan Kelly Bufano; Peng Xu; Grace Eckhoff; Richelle C Charles; Mohammad Murshid Alam; Tania Sultana; Md Rasheduzzaman Rashu; Amanda Berger; Geoffrey Gonzalez-Escobedo; Anjali Mandlik; Taufiqur Rahman Bhuiyan; Daniel T Leung; Regina C LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2015-07-08

Review 7.  Cholera diagnosis in human stool and detection in water: protocol for a systematic review of available technologies.

Authors:  Karin Diaconu; Jennifer Falconer; Fiona O'May; Miguel Jimenez; Joe Matragrano; Betty Njanpop-Lafourcade; Alastair Ager
Journal:  Syst Rev       Date:  2018-02-20

Review 8.  Missed vaccinations and critical care admission: all you may wish to know or rediscover-a narrative review.

Authors:  Laure F Pittet; Mohamed Abbas; Claire-Anne Siegrist; Didier Pittet
Journal:  Intensive Care Med       Date:  2019-11-26       Impact factor: 17.440

Review 9.  The effectiveness of public health interventions to reduce the health impact of climate change: a systematic review of systematic reviews.

Authors:  Maha Bouzid; Lee Hooper; Paul R Hunter
Journal:  PLoS One       Date:  2013-04-25       Impact factor: 3.240

10.  Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.

Authors:  Mohammad Murshid Alam; Megan Kelly Bufano; Peng Xu; Anuj Kalsy; Y Yu; Y Wu Freeman; Tania Sultana; Md Rasheduzzaman Rashu; Ishaan Desai; Grace Eckhoff; Daniel T Leung; Richelle C Charles; Regina C LaRocque; Jason B Harris; John D Clements; Stephen B Calderwood; Firdausi Qadri; W F Vann; Pavol Kováč; Edward T Ryan
Journal:  PLoS Negl Trop Dis       Date:  2014-02-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.